Details
Stereochemistry | UNKNOWN |
Molecular Formula | C10H12ClNO4 |
Molecular Weight | 245.66 |
Optical Activity | ( + ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)OCC(O)COC1=CC=C(Cl)C=C1
InChI
InChIKey=SKPLBLUECSEIFO-UHFFFAOYSA-N
InChI=1S/C10H12ClNO4/c11-7-1-3-9(4-2-7)15-5-8(13)6-16-10(12)14/h1-4,8,13H,5-6H2,(H2,12,14)
DescriptionSources: doi:10.1001/jama.1966.03100220075024Curator's Comment: description was created based on several sources, including:
http://www.drugs.com/mtm/chlorphenesin.html
http://www.drugbank.ca/drugs/DB00856
https://en.wikipedia.org/wiki/Chlorphenesin
Sources: doi:10.1001/jama.1966.03100220075024
Curator's Comment: description was created based on several sources, including:
http://www.drugs.com/mtm/chlorphenesin.html
http://www.drugbank.ca/drugs/DB00856
https://en.wikipedia.org/wiki/Chlorphenesin
Chlorphenesin carbamate (Maolate, Musil) is a centrally acting muscle relaxant used to treat muscle pain and spasms. Сhlorphenesin acts in the central nervous system (CNS) rather than directly on skeletal muscle. It also has antifungal and some antibacterial properties. The major adverse effects are drowsiness and dizziness.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: nerve impulses Sources: https://www.drugs.com/mtm/maolate.html |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: DOI:10.1001/jama.1966.03100220075024 |
Primary | MAOLATE Approved UseUnknown Launch Date1965 |
||
Curative | MAOLATE Approved UseUnknown Launch Date1965 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5133920/ |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: METHOCARBAMOL |
CHLORPHENESIN CARBAMATE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
84 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5133920/ |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: METHOCARBAMOL |
CHLORPHENESIN CARBAMATE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.44 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5133920/ |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: METHOCARBAMOL |
CHLORPHENESIN CARBAMATE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Relative bioavailability of generic and branded 250-mg and 500-mg oral chlorphenesin carbamate tablets in healthy Korean volunteers: a single-dose, randomized-sequence, open-label, two-period crossover trial. | 2009 Nov |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
Sample Use Guides
for adults is 1.6 to 2.4 gm given in divided doses
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6967526
chlorphenesin carbamate (CPC) has an apparent depressing action on the spinal neuron. CPC caused marked hyperpolarizations and depressed spontaneous activities in both of the primary afferent terminals (PAT) and motoneurons (MN).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
G014XC07GH
Created by
admin on Sat Dec 16 10:51:06 GMT 2023 , Edited by admin on Sat Dec 16 10:51:06 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD